Monoclonal antibodies in treatment of multiple sclerosis

Summary Monoclonal antibodies (m A bs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti‐alpha4‐integrin m A b natalizumab in 2004 and 2006, m A bs have gained relevance in the treatment of multiple sclerosis ( MS ). At present, numerous m A bs have been tested in clinical trials in relapsing–remitting MS , and in progressive forms of MS . One of the agents that might soon be approved for very active forms of relapsing–remitting MS is alemtuzumab, a humanized m A b against CD 52. This review provides insights into clinical studies with the m A bs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.